We are live on
!
Find out more
TCM
TCG Crossover Management Portfolio holdings
AUM
$4.16B
1-Year Est. Return
983.43%
This Fund
S&P 500
This Quarter
Est. Return
+6.48%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$513M
AUM Growth
-$53.6M
(-9.5%)
Cap. Flow
-$40.9M
Cap. Flow
% of AUM
-7.98%
Top 10 Holdings %
Top 10 Hldgs %
77.97%
Holding
24
New
3
Increased
3
Reduced
5
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dyne Therapeutics
DYN
|
+$21.4M |
| 2 |
Structure Therapeutics
GPCR
|
+$8.22M |
| 3 |
C4 Therapeutics
CCCC
|
+$7.36M |
| 4 |
Geron
GERN
|
+$7.32M |
| 5 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$6.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$37.6M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
+$22.9M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
+$10.5M |
| 4 |
Viridian Therapeutics
VRDN
|
+$10.3M |
| 5 |
Aclaris Therapeutics
ACRS
|
+$7.81M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $125M | 24.38% |
5,141,118
| – | – |
|
2
Cogent Biosciences
COGT
$6.02B
| $39.2M | 7.64% |
3,631,042
| – | – |
|
|
3
Geron
GERN
$970M
| $38.6M | 7.51% |
17,765,213
+2,578,140
| +17% | +$7.32M |
|
|
4
Madrigal Pharmaceuticals
MDGL
$12.3B
| $36.3M | 7.08% |
149,917
-138,137
| -48% | -$37.6M |
|
5
Tyra Biosciences
TYRA
$1.49B
| $32M | 6.23% |
1,989,103
| – | – |
|
|
VTYX
6
DELISTED
Ventyx Biosciences
VTYX
| $27.3M | 5.33% |
815,724
+28,493
| +4% | +$1.11M |
|
|
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
| $26.7M | 5.2% |
3,395,495
| – | – |
|
|
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
| $26.6M | 5.18% |
3,048,257
-2,857,143
| -48% | -$22.9M |
|
|
VECT
9
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $26.5M | 5.16% |
3,113,600
+780,300
| +33% | +$6.43M |
|
|
JBIO
10
Jade Biosciences
JBIO
$1.33B
| $21.8M | 4.25% |
30,894
| – | – |
|
|
11
Dyne Therapeutics
DYN
$4.68B
| $19M | 3.71% |
+1,650,150
| New | +$21.4M |
|
12
Kura Oncology
KURA
$1.13B
| $17.4M | 3.39% |
1,423,642
| – | – |
|
|
13
Viridian Therapeutics
VRDN
$2.61B
| $16.9M | 3.29% |
663,610
-320,000
| -33% | -$10.3M |
|
|
SLN
14
Silence Therapeutics
SLN
$834M
| $13.1M | 2.54% |
2,104,875
| – | – |
|
15
Immunovant
IMVT
$8.51B
| $10.2M | 1.98% |
654,853
-200,000
| -23% | -$3.47M |
|
16
Entrada Therapeutics
TRDA
$273M
| $8.48M | 1.65% |
584,955
| – | – |
|
|
17
Structure Therapeutics
GPCR
$3.38B
| $8.33M | 1.62% |
+350,000
| New | +$8.22M |
|
|
MRUS
18
DELISTED
Merus
MRUS
| $5.52M | 1.08% |
300,000
| – | – |
|
|
19
Aclaris Therapeutics
ACRS
$885M
| $4.29M | 0.84% |
529,839
-615,100
| -54% | -$7.81M |
|
20
Cabaletta Bio
CABA
$529M
| $4.03M | 0.78% |
486,795
| – | – |
|
|
21
C4 Therapeutics
CCCC
$474M
| $3.92M | 0.77% |
+1,250,000
| New | +$7.36M |
|
|
ALPN
22
DELISTED
Alpine Immune Sciences Inc
ALPN
| $1.95M | 0.38% |
253,069
| – | – |
|
|
ELEV
23
DELISTED
Elevation Oncology
ELEV
| – | – |
-288,390
| Closed | -$274K |
|
|
24
MoonLake Immunotherapeutics
MLTX
$1.28B
| – | – |
-1,000,000
| Closed | -$10.5M |
|
Similar funds
GCM
CC
CIC
LWCA
CWG
MSI
CAM
JFG
TCG Crossover Management's Q1 2023 Portfolio in Review
As of Q1 2023, TCG Crossover Management held 24 positions worth $513M, down 9.5% from $567M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
TCG Crossover Management withdrew a net $40.9M in Q1 2023, closing 2 positions and reducing 5 holdings. Its most notable exit was MoonLake Immunotherapeutics, an estimated $10.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, TCG Crossover Management opened a new position in Dyne Therapeutics worth $19M.
- TCG Crossover Management's largest Q1 2023 buy was Dyne Therapeutics: 1,650,150 shares worth $19M.
- TCG Crossover Management added most to Geron in Q1 2023, an estimated $7.32M increase.
- TCG Crossover Management's biggest Q1 2023 reduction was Madrigal Pharmaceuticals, cutting an estimated $37.6M.
- TCG Crossover Management fully exited MoonLake Immunotherapeutics in Q1 2023, selling an estimated $10.5M.
- TCG Crossover Management's ten largest holdings make up 78% of its $513M portfolio in Q1 2023.
- TCG Crossover Management opened 3 new positions and closed 2 in Q1 2023.
- TCG Crossover Management's portfolio value fell 9.5% quarter-over-quarter to $513M.
Based on TCG Crossover Management's 13F filing for Q1 2023, filed 15 May 2023.